Stereotaxis Announces Convertible Note Financing of Up To $24 Million
Globe Newswire•10/11/2026•16:01 ET
0
Key Highlights
- ➤Convertible note financing up to $24 million announced by Stereotaxis (STXS)
- ➤Initial $12 million closing completed, with another $12 million available
- ➤Notes carry 10% annual interest and mature in three years
- ➤Conversion price $1.21 per share, a 30% premium to the 10-day VWAP
- ➤Pro forma cash reaches $16 million, with total availability of $28 million
Expert Statements
David Fischel, Chairman and CEO of Stereotaxis
“We appreciate the confidence and support from several of our long-term shareholders in this oversubscribed financing.”
David Fischel, Chairman and CEO of Stereotaxis
“Our strengthened balance sheet positions us to execute our strategy and accelerate adoption of our comprehensive portfolio of innovations.”
ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for a convertible note financing of up to $24 million.
“We appreciate the confidence and support from several of our long-term shareholders in this oversubscribed financing,” said David Fischel, Chairman and CEO. “Our strengthened balance sheet positions us to execute our strategy and accelerate adoption of our comprehensive portfolio of innovations.”
Get started
Create a free account to read the full story.